Lidocaine patch (5%) is no more potent than placebo in treating chronic back pain when tested in a randomised double blind placebo controlled brain imaging study

Molecular Pain

Volumn 8, Issue , 2012, Pages

  Hashmi, Javeria A ^a   Baliki, Marwan N ^a   Huang, Lejian ^a   Parks, Elle L ^a   Chanda, Mona L ^a   Schnitzer, Thomas ^a   Apkarian, A V ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Chronic pain; Clinical trial; fmri; Lidocaine; Placebo; Topical analgesic

Indexed keywords

LIDOCAINE; PLACEBO;

ADULT; ANTERIOR CINGULATE; ARTICLE; BACKACHE; BECK ANXIETY INVENTORY; BECK DEPRESSION INVENTORY; CHRONIC BACK PAIN; CHRONIC PAIN; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; LONGITUDINAL STUDY; MALE; MCGILL PAIN QUESTIONNAIRE; MEDIAL PREFRONTAL CORTEX; MEDICATION QUANTIFICATION SCALE; NEUROIMAGING; NEUROPATHIC PAIN SCALE; PAIN ASSESSMENT; PREFRONTAL CORTEX; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE;

BACK PAIN; BRAIN; BRAIN MAPPING; CHRONIC PAIN; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LIDOCAINE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROIMAGING; PLACEBO EFFECT; TRANSDERMAL PATCH;

EID: 84862230311     PISSN: None     EISSN: 17448069     Source Type: Journal    
DOI: 10.1186/1744-8069-8-29     Document Type: Article

References (44)

1. Devor M, Wall PD, Catalan N. Systemic lidocaine silences ectopic neuroma and DRG discharge without blocking nerve conduction. Pain 1992, 48:261-268. 10.1016/0304-3959(92)90067-L, 1589245.
2. Attal N, Gaude V, Brasseur L, Dupuy M, Guirimand F, Parker F, Bouhassira D. Intravenous lidocaine in central pain: a double-blind, placebo-controlled, psychophysical study. Neurology 2000, 54:564-574. 10.1212/WNL.54.3.564, 10680784.
3. Koppert W, Dern SK, Sittl R, Albrecht S, Schuttler J, Schmelz M. A new model of electrically evoked pain and hyperalgesia in human skin: the effects of intravenous alfentanil, S(+)-ketamine, and lidocaine. Anesthesiology 2001, 95:395-402. 10.1097/00000542-200108000-00022, 11506112.
4. Seifert F, Bschorer K, De Col R, Filitz J, Peltz E, Koppert W, Maihofner C. Medial prefrontal cortex activity is predictive for hyperalgesia and pharmacological antihyperalgesia. J Neurosci 2009, 29:6167-6175. 10.1523/JNEUROSCI.4654-08.2009, 19439594.
5. Koppert W, Ostermeier N, Sittl R, Weidner C, Schmelz M. Low-dose lidocaine reduces secondary hyperalgesia by a central mode of action. Pain 2000, 85:217-224. 10.1016/S0304-3959(99)00268-7, 10692621.
6. Luo Z, Yu M, Smith SD, Kritzer M, Du C, Ma Y, Volkow ND, Glass PS, Benveniste H. The effect of intravenous lidocaine on brain activation during non-noxious and acute noxious stimulation of the forepaw: a functional magnetic resonance imaging study in the rat. Anesth Analg 2009, 108:334-344. 10.1213/ane.0b013e31818e0d34, 2681082, 19095870.
7. Tremont-Lukats IW, Challapalli V, McNicol ED, Lau J, Carr DB. Systemic administration of local anesthetics to relieve neuropathic pain: a systematic review and meta-analysis. Anesth Analg 2005, 101:1738-1749.
8. Woolf CJ, Wiesenfeld-Hallin Z. The systemic administration of local anaesthetics produces a selective depression of C-afferent fibre evoked activity in the spinal cord. Pain 1985, 23:361-374. 10.1016/0304-3959(85)90006-5, 3937116.
9. Gammaitoni AR, Alvarez NA, Galer BS. Pharmacokinetics and safety of continuously applied lidocaine patches 5%. Am J Health Syst Pharm 2002, 59:2215-2220.
10. Ko JC, Maxwell LK, Abbo LA, Weil AB. Pharmacokinetics of lidocaine following the application of 5% lidocaine patches to cats. J Vet Pharmacol Ther 2008, 31:359-367. 10.1111/j.1365-2885.2008.00967.x, 18638297.
11. Krumova EK, Zeller M, Westermann A, Maier C. Lidocaine patch (5%) produces a selective, but incomplete block of Adelta and C fibers. Pain 2012, 153:273-280. 10.1016/j.pain.2011.08.020, 21995882.
12. Lam VY, Wallace M, Schulteis G. Effects of lidocaine patch on intradermal capsaicin-induced pain: a double-blind, controlled trial. J Pain 2011, 12:323-330. 10.1016/j.jpain.2010.07.013, 20889387.
13. Wehrfritz A, Namer B, Ihmsen H, Mueller C, Filitz J, Koppert W, Leffler A. Differential effects on sensory functions and measures of epidermal nerve fiber density after application of a lidocaine patch (5%) on healthy human skin. Eur J Pain 2011, 15:907-912. 10.1016/j.ejpain.2011.03.011, 21530339.
14. Campbell JN. How does topical lidocaine relieve pain. Pain 2012, 153:255-256. 10.1016/j.pain.2011.10.011, 22055552.
15. Baron R, Mayoral V, Leijon G, Binder A, Steigerwald I, Serpell M. 5% lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: an open-label, non-inferiority two-stage RCT study. Curr Med Res Opin 2009, 25:1663-1676. 10.1185/03007990903047880, 19485723.
16. Baron R, Mayoral V, Leijon G, Binder A, Steigerwald I, Serpell M. Efficacy and safety of combination therapy with 5% lidocaine medicated plaster and pregabalin in post-herpetic neuralgia and diabetic polyneuropathy. Curr Med Res Opin 2009, 25:1677-1687. 10.1185/03007990903048078, 19480610.
17. Binder A, Bruxelle J, Rogers P, Hans G, Bosl I, Baron R. Topical 5% lidocaine (lignocaine) medicated plaster treatment for post-herpetic neuralgia: results of a double-blind, placebo-controlled, multinational efficacy and safety trial. Clin Drug Investig 2009, 29:393-408. 10.2165/00044011-200929060-00003, 19432499.
18. Argoff CE, Galer BS, Jensen MP, Oleka N, Gammaitoni AR. Effectiveness of the lidocaine patch 5% on pain qualities in three chronic pain states: assessment with the Neuropathic Pain Scale. Curr Med Res Opin 2004, 20(Suppl 2):S21-S28.
19. Galer BS, Gammaitoni AR, Oleka N, Jensen MP, Argoff CE. Use of the lidocaine patch 5% in reducing intensity of various pain qualities reported by patients with low-back pain. Curr Med Res Opin 2004, 20(Suppl 2):S5-S12.
20. Baliki MN, Geha PY, Jabakhanji R, Harden N, Schnitzer TJ, Apkarian AV. A preliminary fMRI study of analgesic treatment in chronic back pain and knee osteoarthritis. Mol Pain 2008, 4:47. 10.1186/1744-8069-4-47, 2584040, 18950528.
21. Herrmann DN, Barbano RL, Hart-Gouleau S, Pennella-Vaughan J, Dworkin RH. An open-label study of the lidocaine patch 5% in painful idiopathic sensory polyneuropathy. Pain Med 2005, 6:379-384. 10.1111/j.1526-4637.2005.00058.x, 16266359.
22. Geha PY, Baliki MN, Chialvo DR, Harden RN, Paice JA, Apkarian AV. Brain activity for spontaneous pain of postherpetic neuralgia and its modulation by lidocaine patch therapy. Pain 2007, 128:88-100. 10.1016/j.pain.2006.09.014, 1850186, 17067740.
23. Galer BS, Sheldon E, Patel N, Codding C, Burch F, Gammaitoni AR. Topical lidocaine patch 5% may target a novel underlying pain mechanism in osteoarthritis. Curr Med Res Opin 2004, 20:1455-1458. 10.1185/030079904X2754, 15383194.
24. Gimbel J, Linn R, Hale M, Nicholson B. Lidocaine patch treatment in patients with low back pain: results of an open-label, nonrandomized pilot study. Am J Ther 2005, 12:311-319. 10.1097/01.mjt.0000164828.57392.ba, 16041194.
25. Hines R, Keaney D, Moskowitz MH, Prakken S. Use of lidocaine patch 5% for chronic low back pain: a report of four cases. Pain Med 2002, 3:361-365. 10.1046/j.1526-4637.2002.02051.x, 15099246.
26. Nicolaou A, Nicholson B, Hans G, Brasseur L. Outcome predictors for treatment success with 5% lidocaine medicated plaster in low back pain with neuropathic components and neuropathic pain after surgical and nonsurgical trauma. J Pain Res 2011, 4:25-38. 3048580, 21386952.
27. Galer BS, Jensen MP, Ma T, Davies PS, Rowbotham MC. The lidocaine patch 5% effectively treats all neuropathic pain qualities: results of a randomized, double-blind, vehicle-controlled, 3-week efficacy study with use of the neuropathic pain scale. Clin J Pain 2002, 18:297-301. 10.1097/00002508-200209000-00004, 12218500.
28. Morlion B. Pharmacotherapy of low back pain: targeting nociceptive and neuropathic pain components. Curr Med Res Opin 2011, 27:11-33. 10.1185/03007995.2010.534446, 21083513.
29. Dworkin RH, Jensen MP, Gould E, Jones BA, Xiang Q, Galer BS, Gammaitoni AR. Treatment Satisfaction in Osteoarthritis and Chronic Low Back Pain: The Role of Pain, Physical and Emotional Functioning, Sleep, and Adverse Events. J Pain 2010, 12:416-424.
30. Benedetti F, Carlino E, Pollo A. How placebos change the patient's brain. Neuropsychopharmacology 2011, 36:339-354. 10.1038/npp.2010.81, 3055515, 20592717.
31. Wager TD, Atlas LY, Leotti LA, Rilling JK. Predicting individual differences in placebo analgesia: contributions of brain activity during anticipation and pain experience. J Neurosci 2011, 31:439-452. 10.1523/JNEUROSCI.3420-10.2011, 21228154.
32. Zubieta JK, Stohler CS. Neurobiological mechanisms of placebo responses. Ann N Y Acad Sci 2009, 1156:198-210. 10.1111/j.1749-6632.2009.04424.x, 3073412, 19338509.
33. Scott DJ, Stohler CS, Egnatuk CM, Wang H, Koeppe RA, Zubieta JK. Individual differences in reward responding explain placebo-induced expectations and effects. Neuron 2007, 55:325-336. 10.1016/j.neuron.2007.06.028, 17640532.
34. Scott DJ, Stohler CS, Egnatuk CM, Wang H, Koeppe RA, Zubieta JK. Placebo and nocebo effects are defined by opposite opioid and dopaminergic responses. Arch Gen Psychiatry 2008, 65:220-231. 10.1001/archgenpsychiatry.2007.34, 18250260.
35. Benedetti F. Mechanisms of placebo and placebo-related effects across diseases and treatments. Annu Rev Pharmacol Toxicol 2008, 48:33-60. 10.1146/annurev.pharmtox.48.113006.094711, 17666008.
36. Tracey I. Getting the pain you expect: mechanisms of placebo, nocebo and reappraisal effects in humans. Nat Med 2010, 16:1277-1283. 10.1038/nm.2229, 20948533.
37. Beauregard M. Effect of mind on brain activity: evidence from neuroimaging studies of psychotherapy and placebo effect. Nord J Psychiatry 2009, 63:5-16. 10.1080/08039480802421182, 19023697.
38. Bingel U, Wanigasekera V, Wiech K, Ni Mhuircheartaigh R, Lee MC, Ploner M, Tracey I. The effect of treatment expectation on drug efficacy: imaging the analgesic benefit of the opioid remifentanil. Sci Transl Med 2011, 3:70ra14. 10.1126/scitranslmed.3001244, 21325618.
39. Baliki MN, Chialvo DR, Geha PY, Levy RM, Harden RN, Parrish TB, Apkarian AV. Chronic pain and the emotional brain: specific brain activity associated with spontaneous fluctuations of intensity of chronic back pain. J Neurosci 2006, 26:12165-12173. 10.1523/JNEUROSCI.3576-06.2006, 17122041.
40. Baliki MN, Geha PY, Apkarian AV. Parsing pain perception between nociceptive representation and magnitude estimation. J Neurophysiol 2009, 101:875-887.
41. Smith SM, Jenkinson M, Woolrich MW, Beckmann CF, Behrens TE, Johansen-Berg H, Bannister PR, De Luca M, Drobnjak I, Flitney DE, et al. Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage 2004, 23(Suppl 1):S208-S219.
42. Woolrich MW, Ripley BD, Brady M, Smith SM. Temporal autocorrelation in univariate linear modeling of FMRI data. Neuroimage 2001, 14:1370-1386. 10.1006/nimg.2001.0931, 11707093.
43. Woolrich MW, Behrens TE, Beckmann CF, Jenkinson M, Smith SM. Multilevel linear modelling for FMRI group analysis using Bayesian inference. Neuroimage 2004, 21:1732-1747. 10.1016/j.neuroimage.2003.12.023, 15050594.
44. Friston KJ, Frith CD, Turner R, Frackowiak RS. Characterizing evoked hemodynamics with fMRI. Neuroimage 1995, 2:157-165. 10.1006/nimg.1995.1018, 9343598.